The NHS is set to accelerate the delivery of theweight-loss drug Mounjaroas part of a significant strategic shift in the 2026/27 GP contract. Announced on 23 February 2026, the new government obesity strategy introduces financial incentives for General Practitioners to move weight management from specialist clinics into local surgeries. This transition aims to address a public health crisis that currently costs the health service an estimated £11 billion (approximately $14.8 billion) annually.
Under the new framework, theDepartment of Health and Social Care (DHSC)seeks to decentralise treatment by offering bonuses to practices that meet specific prescribing targets. By moving these services into primary care, the government intends to reduce the pressure on hospital-based specialist weight management tiers. The initiative is being positioned as a fundamental change in how the British state manages long-term metabolic health.
The strategy also aims to tackle the 'postcode lottery' of care, where access to GLP-1 receptor agonists has previously been dictated by local funding variations. Health Secretary Wes Streeting told theBBCthat these incentives are designed to end a two-tier system where access often depends on an individual's private wealth. The goal is to ensure the medication reaches those with the greatest clinical need regardless of their geographic location.
Despite the national mandate for wider access, aBritish Medical Journal(BMJ)investigation in January 2026 found that one in five local areas still lacked a functional NHS pathway for Mounjaro. TheseIntegrated Care Boards (ICBs)have been criticised for unacceptable delays in implementing the rollout. These regional gaps are reportedly pushing some patients toward an unregulated black market for GLP-1 drugs, which poses significant safety risks.
The 2026 strategy aims to resolve these regional discrepancies by streamlining the pathway through primary care settings. By July 2026, a new £85 millionprogramme co-funded by the governmentand the manufacturer,Eli Lilly, is expected to launch. This initiative will test additional routes for access through community pharmacies and digital health platforms to ensure that patients are not reliant solely on their local GP surgery for initial consultations.
The UK government, in partnership with Lilly, has launched an £85 million pilot to transform obesity care.From summer 2026, local pharmacies, digital services, and community hubs will be able to provide patients with tailored weight management support,https://t.co/vFp5xOnDstpic.twitter.com/ZvjBCdqkjo
As part of the updated GP contract, practices in England will be offered a bonus of up to £3,000 (around $4,000) for actively managing patients onweight-loss injections such as tirzepatide. This is supported by £25 million (approximately $33.7 million) in ring-fenced funding. Key updates to theQuality and Outcomes Framework (QOF) for 2026include new indicators where GPs will be monitored on their provision of obesity care and the recording of patient BMI.
Furthermore, GPs are now being explicitly encouraged to manage 'wraparound care.' This involves mandatory nutritional and behavioural support that must accompany the medication to ensure long-term efficacy. This support is intended to prevent the medication from being used as a standalone intervention without the necessary lifestyle adjustments.
Theeligibility criteriafor receiving the treatment through primary care have undergone a phased expansion. In 2025, access was reserved for patients with a BMI of 40 or higher who also presented with four weight-related conditions. Under the new 2026/27 framework, these requirements have been lowered to include those with a BMI of 35 and four conditions, or a BMI of 40 with three conditions.
Boots launches walk-in Mounjaro and Wegovy weight loss jabs on UK high streetsPharmacy giant Boots is trialling in-person consultations in 17 stores nationwide, letting patients get quick eligibility checks and prescriptions without a GP referral.Previously mostly online, the…pic.twitter.com/4isWQncOBg
Source: International Business Times UK
